RESUMO
The development of cost-effective and energy-efficient technologies for the stabilization of organic wastewater by microalgae has been essential and sought after. In the current study, GXU-A4 was isolated from an aerobic tank treating molasses vinasse (MV) and identified as Desmodesmus sp. based on its morphology, rbcL, and ITS sequences. It exhibited good growth with a high lipid content and chemical oxygen demand (COD) when grown using MV and the anaerobic digestate of MV (ADMV) as the growth medium. Three distinct COD concentrations for wastewater were established. Accordingly, GXU-A4 removed more than 90% of the COD from molasses vinasse (MV1, MV2, and MV3) with initial COD concentrations of 1193 mgL-1, 2100 mgL-1, and 3180 mgL-1, respectively. MV1 attained the highest COD and color removal rates of 92.48% and 64.63%, respectively, and accumulated 47.32% DW (dry weight) of lipids and 32.62% DW of carbohydrates, respectively. Moreover, GXU-A4 grew rapidly in anaerobic digestate of MV (ADMV1, ADMV2, and ADMV3) with initial COD concentrations of 1433 mgL-1, 2567 mgL-1, and 3293 mgL-1, respectively. Under ADMV3 conditions, the highest biomass reached 13.81 g L-1 and accumulated 27.43% DW of lipids and 38.70% DW of carbohydrates, respectively. Meanwhile, the removal rates of NH4-N and chroma in ADMV3 reached 91.10% and 47.89%, respectively, significantly reducing the concentration of ammonia nitrogen and color in ADMV. Thus, the results demonstrate that GXU-A4 has a high fouling tolerance, a rapid growth rate in MV and ADMV, the ability to achieve biomass accumulation and nutrient removal from wastewater, and a high potential for MV recycling.
Assuntos
Microalgas , Águas Residuárias , Melaço , Carboidratos , Biomassa , Nitrogênio , LipídeosRESUMO
Background: Although the efficacy and safety of monotherapy in the treatment of benign prostatic hyperplasia (BPH) have been established clinically, the efficacy and safety of dutasteride and finasteride have not been compared. The aim was to systematically evaluate the efficacy and safety of the two drugs in the treatment of BPH to provide medical evidence for clinical treatment. Methods: A search of relevant articles was conducted using the electronic databases PubMed, Embase, Medline, Cochrane Library, China Academic Journals Full-text Database (CJFD), Chinese Science and Technology Journal Database (VIP) and Wanfang Database. Randomized controlled trials (RCTs) comparing the efficacy of finasteride (control group) with that of dutasteride (experimental group) in the treatment of BPH with respect to the International Prostate Symptom Score (IPSS), the maximum urinary flow rate (Qmax), prostate volume (PV), quality of life (QOL), serum prostate-specific antigen (PSA) level and adverse drug reactions (ADRs) after medication were strictly evaluated and considered for inclusion. Rev Man 5.4 software was used for the meta-analysis. Results: A total of 8 RCTs were included, with a total of 2,116, patients. The meta-analysis showed that compared with finasteride, dutasteride can effectively improve the Qmax of patients with BPH [mean difference (MD) =0.32; 95% confidence interval (CI): (0.01, 0.63); P=0.04]. There was no significant difference in reducing IPSS [MD =0.13; 95% CI: (-0.55, 0.82); P=0.70], improving PV [MD =-1.25; 95% CI: (-3.30, 0.79); P=0.23], reducing QOL [MD =-0.44; 95% CI: (-0.93, 0.05); P=0.08] and serum PSA level [MD =-0.04; 95% CI: (-0.15, 0.07); P=0.50], and the occurrence of ADRs [relative risk (RR) =-0.01; 95% CI: (-0.05, 0.04); P=0.72], there was no significant difference. Discussion: Dutasteride is better than finasteride in improving the Qmax of patients with BPH. There was no statistically significant difference in symptoms, PV, PSA, QOL, or adverse reactions. Dutasteride is an effective and safe treatment for BPH. Due to the limitations of the methodological quality and sample size of the included studies, this conclusion needs to be verified by stratified RCTS with high volumes and long follow-up times.
RESUMO
BACKGROUND: Bone metastasis is the leading cause of mortality and reduced quality of life in patients with metastatic prostate cancer (PCa). Long non-coding RNA activated by DNA damage (NORAD) has been observed to have an abnormal expression in various cancers. This article aimed to explore the molecular mechanism underlying the regulatory role of NORAD in bone metastasis of PCa. METHODS: NORAD expression in clinical PCa tissues and cell lines was detected with the application of qRT-PCR. Cancer cells were then transfected with plasmids expressing NORAD, after which Transwell assay and CCK-8 assay were carried out to detect proliferation, migration, and bone metastasis of PCa. NORAD downstream target molecules were screened through bioinformatics analysis, followed by further verification using dual luciferase assay. Extracellular vesicles (EVs) were labeled with PKH67 and interacted with bone marrow stromal cells. The gain- and loss-function method was applied to determine the internalization and secretion of PCa cells-derived EVs under the intervention of downstream target molecules or NORAD. RESULTS: PCa tissues and cell lines were observed to have a high expression of NORAD, particularly in tissues with bone metastasis. NORAD knockdown resulted in reduced secretion and internalization of EVs, and suppressed proliferation, migration, and bone metastasis of PCa cells. It was indicated that NORAD interacted with miR-541-3p, leading to the upregulation of PKM2. Forced expression of PKM2 promoted the transfer of PKH67-labeled EVs to bone marrow stromal cells. CONCLUSIONS: NORAD might serve as a ceRNA of miR-541-3p to promote PKM2 expression, thereby enhancing the development of bone metastasis in PCa by promoting internalization and transfer of EVs of cancer cells, providing an insight into a novel treatment for the disorder.
